Compounded medication
Compounded tirzepatide.
Tirzepatide acts on both the GIP and GLP-1 receptors. Like semaglutide, it slows gastric emptying and influences appetite signaling. Whether it is a fit for you is a clinical decision made by a licensed clinician after reviewing your health history.
- Once-weekly subcutaneous injection, dosed by your clinician
- Dual GIP and GLP-1 receptor activity
- Compounded and dispensed by Rush Pharmacy, shipped to your door
- Dose-adjustment reviews and side-effect support included
Common questions
- Is compounded tirzepatide the same as brand-name tirzepatide?
- No. Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual patient and is not FDA-approved or reviewed by the FDA for safety or effectiveness.
- How does tirzepatide differ from semaglutide?
- Tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide acts on GLP-1 alone. Your clinician recommends which option fits your history and goals.
- Who dispenses the medication?
- Rush Pharmacy compounds and ships your medication directly to your door in temperature-controlled packaging.
- Where is treatment available?
- Vida Suya serves 49 states. We do not serve California. A prescription is only issued if a licensed clinician determines treatment is appropriate.
Compounded tirzepatide is not FDA-approved and is not reviewed by the FDA for safety or effectiveness. It is prepared by a licensed compounding pharmacy for an individual patient when a clinician determines it is appropriate.
Common side effects include nausea, vomiting, diarrhea and constipation. Serious risks may include pancreatitis, gallbladder disease and thyroid C-cell tumors in animal studies. Do not use if you or a family member has had medullary thyroid carcinoma or MEN2. Not for use during pregnancy or breastfeeding.
Available in 49 states (not California). No prescription, medication or specific result is guaranteed. Individual results vary.